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To develop a tool for estimating the 10-year risk of death from other causes in men with
localized prostate cancer.
Subjects and methods
We identified 2,425 patients from the Surveillance Epidemiology and End Results—Medi-
care Health Outcomes Survey database, age <80, newly diagnosed with clinical stage T1-
T3a prostate cancer from 1/1/1998-12/31/2009, with follow-up through 2/28/2013. We
developed a Fine and Gray competing-risks model for 10-year other cause mortality consid-
ering age, patient-reported comorbid medical conditions, component scores and items of
the SF-36 Health Survey, activities of daily living, and sociodemographic characteristics.
Model discrimination and calibration were compared to predictions from Social Security life
table mortality risk estimates.
Results
Over a median follow-up of 7.7 years, 76 men died of prostate-specific causes and 465 died of
other causes. The strongest predictors of 10-year other cause mortality risk included increasing
age at diagnosis, higher approximated Charlson Comorbidity Index score, worse patient-
reported general health (fair or poor vs. excellent-good), smoking at diagnosis, and marital sta-
tus (all other vs. married) (all p<0.05). Model discrimination improved over Social Security life
tables (c-index of 0.70 vs. 0.59, respectively). Predictions were more accurate than predictions
from the Social Security life tables, which overestimated risk in our population.
PLOS ONE







Citation: Frendl DM, FitzGerald G, Epstein MM,
Allison JJ, Sokoloff MH, Ware JE (2020) Predicting
the 10-year risk of death from other causes in men
with localized prostate cancer using patient-
reported factors: Development of a tool. PLoS ONE
15(12): e0240039. https://doi.org/10.1371/journal.
pone.0240039
Editor: Matteo Rota, Universita degli Studi di
Brescia, ITALY
Received: January 13, 2020
Accepted: September 17, 2020
Published: December 7, 2020
Copyright: © 2020 Frendl et al. This is an open
access article distributed under the terms of the
Creative Commons Attribution License, which
permits unrestricted use, distribution, and
reproduction in any medium, provided the original
author and source are credited.
Data Availability Statement: The full data
underlying the results presented in the study are
available from the National Cancer Institute -
National Institutes of Health through an application
process with a data use agreement. The data are
available to investigators who apply for the SEER-
Medicare Health Outcomes Survey linked data
through an application process managed by the
National Cancer Institute, National Institutes of
Health. Detailed information is available at: (https://
healthcaredelivery.cancer.gov/seer-mhos/). The
Conclusions
We provide a tool for estimating the 10-year risk of dying from other causes when making
decisions about treating prostate cancer using pre-treatment patient-reported
characteristics.
Introduction
Accurate assessment of life expectancy is critical to enabling evidence-based treatment decision-
making for over 230,000 men diagnosed with prostate cancer in the U.S. annually [1]. Guidelines
recommend that clinicians reserve definitive treatment of localized tumors for men with at least a
10-year life expectancy [2]. For men with localized low to intermediate risk tumors, the average
risk of dying of prostate cancer in the 10 years after diagnosis is 5 to 8%, regardless of treatment
[3]. In contrast, the risk of dying of causes other than prostate cancer (termed “other causes”) can
range from as low as 6% to over 90%, depending on a man’s age, health, and social factors [3–6].
Thus, enabling accurate determinations of the risk of dying of other causes is of high importance,
especially given that many men have historically been overtreated—dying of non-prostate causes
within 10 years of treatment–while today a growing number of healthy older men, who may bene-
fit from treatment, may not receive it because of their age alone [6–10].
Individualized mortality risk estimation is currently limited in real-world practice. The
National Comprehensive Cancer Network guidelines recommend using risk estimates from
the Social Security life tables, a method that relies on crude age-based life expectancy estimates
[11,12]. Other available prediction tools, specifically developed for men with prostate cancer,
incorporate both age and comorbidity for assessing other cause mortality risk [3,7,13,14].
There remains limited evidence supporting that these tools are meaningfully better than the
Social Security life tables in assessing 10-year mortality risk [15]. Despite the availability of
these tools, few clinicians use them in practice, most likely because they require busy clinicians’
valuable time to derive estimates [16]. Existing tools have also yet to evaluate whether integra-
tion of age and comorbidity information with patient-reported factors, such as physical func-
tioning and general health, which are increasingly seen as valuable for comprehensively
assessing health and other cause mortality risk, actually improve predictions [14,15,17,18].
Accurate mortality risk prediction is especially important for patients age 65–80, the age group
most frequently receiving a new diagnosis of prostate cancer, who are more likely than youn-
ger men to die of other causes but still are often considered for definitive treatment. This study
sought to identify a combination of pre-treatment patient-reported factors for estimation of
the 10-year risk of death from other causes in men newly diagnosed with localized prostate
cancer. We also sought to provide individualized risk predictions through a supplemental
online risk estimation tool.
Subjects and methods
The University of Massachusetts Medical School Institutional Review Board approved the
study protocol. Given the data were analyzed anonymously using a large retrospective cohort
consent was waived. IRB Review ID: H00002704.
Data source
We used the Surveillance, Epidemiology, and End Results (SEER)—Medicare Health Out-
comes Survey (MHOS) linked database that contains data from 22,023 men diagnosed with
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prostate cancer between 1998–2009, with follow-up through 2/28/2013. The SEER cancer reg-
istry collects sociodemographic, tumor, and treatment data representative of 26% of the U.S.
population [19]. The Centers for Medicare & Medicaid Services’ (CMS) separately conducts
the MHOS survey, annually collecting patient-reported comorbidity and health behavior data
from a sample of Medicare Advantage Organization participants to monitor health outcomes,
with response rates of 64–72% [20]. Medicare Advantage Organization participants represent
roughly 19% of all Medicare beneficiaries. These independent SEER and MHOS databases
have been linked with detailed methods previously reported elsewhere [20].
Study population
Patients were selected if newly diagnosed with prostate cancer between 1/1/1998-12/31/2009,
and completed an MHOS survey within the 3 years preceding their prostate cancer diagnosis.
Exclusion criteria included diagnosis of prostate cancer on autopsy or death certificate or
regionalized or metastasized tumors (stage >cT3a) and men over age 80 at diagnosis. We also
excluded patients with other primary cancers diagnosed before prostate cancer. Age was
restricted for the primary analysis because few men over age 80 have a life expectancy greater
than 10 years and thus age alone may rule out definitive therapy [7]. Detailed exclusions are
available in S1 Fig in S1 File.
Data collected
Age at diagnosis was determined from the SEER registry. Patient-reported comorbidity data
were available as (1) myocardial infarction; (2) congestive heart failure; (3) stroke; (4) emphy-
sema, asthma or chronic obstructive pulmonary disease (COPD); (5) diabetes; (6) any cancer
other than skin cancer; (7) paralysis or weakness on one side of the body; (8) Crohn’s disease,
ulcerative colitis, or inflammatory bowel disease; (9) hypertension; (10) angina or coronary
artery disease; (11) other heart conditions; (12) arthritis of the hip or knee; (13) arthritis of the
hand or wrist; and (14) sciatica. An approximated Charlson Comorbidity Index (CCI) score
was generated using Charlson weights for conditions 1–8, which overlap with the CCI [21].
Patient-reported physical and mental health-related quality of life were measured with the
SF-36 Health Survey (v1) [22], administered to participants before 2006, and the VR-12 Health
Survey [23], for men surveyed in 2006 and after. Physical Component Summary (PCS) and
Mental Component Summary (MCS) scores were utilized as scored by MHOS with an algo-
rithm that allows for comparing scores across SF-36 and VR-12 survey forms [24]. Scores are
normalized to a mean of 50 points in the general U.S. population with a standard deviation of
10 points, with higher scores representing better health. Additionally, we used a single item,
available in both surveys, assessing self-rated general health as excellent, very good, good, fair,
and poor.
Data on activities of daily living were used as the modified Physical-Functioning Activities
of Daily Living scale (PF-ADL), derived from 8 items available across all MHOS survey forms
(moderate activities physical functioning item and ADLs: climbing stairs, bathing, dressing,
eating, getting out of a chair, walking, toileting). This scale was Scores are reported on a 0–100
point scale, with higher scores representing better health.
Patients were considered smokers if reporting smoking every day or some days in MHOS.
Individuals who SEER-MHOS categorized as “unknown smoking status” were considered
non-smokers, as our exploratory analyses revealed they experienced survival similar to non-
smokers. Education was categorized as “more than a high school education” or “high school
education or less” to provide consistency with prior definitions [18]. Race-ethnicity was classi-
fied by SEER-MHOS as non-Hispanic white, non-Hispanic black, Hispanic, Asian/Pacific
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Islander, and other. MHOS variables for marital status (married vs. all other), home owner-
ship, and household income were also assessed. Generally, the “unknown” or “missing” cate-
gories were treated as absence of exposure to the variable of interest. These categorizations
enabled a complete case analysis that included 2,398 men.
Survival and mortality outcomes
Survival was calculated as the difference between the date of diagnosis and the date of death, or
last SEER follow-up date for censored patients. Patients not experiencing death within 10
years of prostate cancer diagnosis were censored at 10 years or at last SEER follow-up if fol-
lowed <10 years. Patients who died were classified as having died of prostate-specific (PCSM)
versus other causes, verified using the SEER cause of death recode variable. Patients missing
follow-up data were excluded.
Statistical analysis
Patient characteristics were compared among those dying of PCSM, OCM, and survivors
using one-way analysis of variance tests and chi-squared tests as appropriate. Overall cumula-
tive incidence of 10-year OCM was computed using a cumulative incidence function, a modi-
fied Kaplan-Meier method that accounts for the competing risk of dying of PCSM.
Fine and Gray competing risks models for 10-year OCM were fitted with PCSM as the com-
peting event [25]. Pre-specified candidate predictors were selected based on prior predictive
value reported in the literature. Candidate variables included age at diagnosis, comorbid medi-
cal conditions (approximated CCI), SF-36/VR12 PCS, SF-36/VR12 MCS, PF-ADL, self-rated
general health, and sociodemographic variables (race, marital status, education level, house-
hold income) [3,13,14,18,26]. Akaike’s Information Criterion (AIC) and Harrell’s c-index
(concordance index) guided model selection to optimize model parsimony and maximize dis-
crimination [27]. Minimizing AIC limits the number of variables selected, penalizing more
complex models that do not substantially fit the data better. Harrell’s c-index assesses a model’s
ability to discriminate between individuals who live and die, ranging from poorest discrimina-
tion of 0.5 to perfect performance at 1.0 [28], and can be adapted to competing-risks models
[29,30]. Interaction terms between age and comorbidity, comorbidity and general health, age
and general health, and smoking and comorbidity were considered to evaluate potential effect
modification. Risk scores were generated from the final model with the equation: risk of





. Calibration of risk scores was assessed
using a goodness of fit test comparing predicted OCM to observed cumulative incidence of
OCM across quartiles of increasing predicted risk.
As a performance benchmark, the new model predictions were compared to the Social
Security life tables [12–14]. Using the Social Security life tables annual risk of mortality,
reported for the general male U.S. population [12], the risk of dying within the next 10 years of
all-causes was computed and assigned to each patient with age rounded to integer values.
Although external data was not available for validating the model, we performed an internal
validation of model discrimination using bootstrapped resampling methods. Briefly, to achieve
an estimate of c-index optimism we re-estimated our model and discrimination in 100 boot-
strapped samples. We then applied the re-estimated model predictions to the original complete
data to also evaluate the discrimination of the new coefficient estimates in the original sample.
Detailed methods are available in S1 Methods in S1 File. As an additional sensitivity analysis,
the performance of the final model was evaluated in a sample including patients over age 80
who were excluded from the primary analysis. Subject characteristics and methods for this
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sensitivity analysis are described in supplementary materials. Additionally, SEER-MHOS
death rates are lower than those observed in some populations, which may lead to systematic
underestimation of mortality risk when applying the final risk estimates in other populations
[7]. To improve the generalizability of the final risk model, exploratory re-calibrated model
estimates are provided in S4 Table in S1 File. Detailed methods are available in S1 Methods in
S1 File. All analyses were performed with Stata 12 (StataCorp, College Station, TX) or SAS 9.3
(SAS, Carry, NC) software, and the protocol is available online [31].
Results
Patient demographics
Mean age at diagnosis was 73 years. The majority of men (54%) had approximated CCI scores
of 0, ranging from 0–7 points, with 21% of the sample having scores of 2 or higher. Compared
to surviving men, those who died of OCM were older, with higher comorbidity burden, had
worse PCS scores, worse general health, and were more likely to be smokers at diagnosis, and
less often married. Overall, 67% of the cohort underwent definitive treatment for prostate can-
cer, the majority of which was radiation therapy. Notably, 56% of patients experiencing OCM
within 10 years of diagnosis were treated aggressively- predominantly with radiation. Full sam-
ple characteristics are summarized in Table 1.
Fine and Gray competing risks regression analysis
Over a median follow-up of 7.7 years, 3.7% of the cohort died of PCSM and 24.3% of OCM.
Median follow-up for survivors was 8.9 years (interquartile range 5.5–11 years). The combina-
tion of patient-reported pre-treatment factors with highest predictive value for death from
OCM included age at diagnosis, approximated Charlson Comorbidity Index score, general
health (excellent to good vs. fair or poor), smoking at time of diagnosis, and marital status
(married vs. all other) (Table 2). The predictors are listed in the order of their respective con-
tribution to the prediction, with age providing the greatest information and marital status pro-
viding the least. The model achieved a c-index of 0.70 vs. 0.59 from the Social Security life
tables. The internal validation detailed in S1 Table in S1 File revealed the range of model dis-
crimination results in the bootstrapped samples was 0.68 to 0.73 with a mean value of 0.70.
The final model with age, approximated CCI score, general health, smoking at diagnosis,
and marital status performed as well as models that included more information about patient-
reported physical and mental health (PCS and MCS) and models that included activities of
daily living (PF-ADL) (c-index was 0.70 for all models with minimal differences in AIC).
Other socioeconomic (education level, household income, homeownership) and race factors
did not have significant associations with OCM in models that included age and approximated
CCI score, except for being in the “other” race category, which did not have a clinically inter-
pretable definition and represented a very few patients (4%). No significant interactions were
observed, except for poor general health and an approximated CCI score of 7, which applied to
<11 individuals and thus was left out of the final model. Model performance also remained
similar in the sensitivity analysis that included patients over age 80 (S2 and S3 Tables in S1
File).
Risk scores
Table 3 shows the range of risk scores obtained from the regression equation in this study pop-
ulation. Median predicted 10-year OCM risk was 20% (interquartile range 15–29%). The
model was well calibrated in the SEER-MHOS population, with observed OCM mirroring
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predicted rates across increasing levels of risk (Table 4); in comparison, the Social Security life
tables over-predicted risk for most patients in this study (Table 4). Example clinical scenarios
where patients have sequentially poorer health and higher OCM risk in each example are avail-
able in S5 Table in S1 File. A dynamic risk calculation tool is available at http://www.
urologyrisk.com.
Discussion
This study developed a prognostic tool for 10-year other cause mortality risk in men newly
diagnosed with prostate cancer. We identified a set of five pre-treatment patient-reported pre-
dictors that performed as well as more extensive and burdensome evaluations of health. While
Table 1. Patient characteristics.
Total Prostate Specific Death Other Cause Mortality Surviving p-value
No. of patients (%) 2425 76 (3) 465 (19) 1884 (78) -
Mean age at diagnosis 72.9 74.5 73.8 72.6 <0.001
Race (%)
Non-Hispanic White 1879 (77) 57 (75) 371 (80) 1451 (77) 0.282
Non-Hispanic Black 290 (12) ~ 55 (12) 223 (12)
Hispanic/Asian/Pacific Islander or other 256 (11) ~ 39 (8) 210 (11)
Approximated Charlson Comorbidity Index Score (%) <0.001
0 1326 (54) 31 (40) 177 (38) 1118 (59)
1 586 (24) 18 (24) 130 (28) 438 (23)
�2 513 (21) 27 (35) 158 (34) 328 (17)
Marital Status
Married vs. all other (%) 1695 (70) 48 (63) 292 (63) 1355 (72) <0.001
Smoker at diagnosis (%) 301 (12) 18 (24) 86 (18) 197 (10) <0.001
Patient-reported Functioning and Wellbeing
PCS (mean, SD) 43.5 (10.9) 41.2 (11.6) 40.1 (11.1) 44.4 (10.4) <0.001
MCS (mean, SD) 53.3 (9.4) 49.3 (10.7) 51.5 (10.4) 53.9 (8.9) <0.001
Physical Functioning—ADL Index (mean, SD)± 87.8 (15.5) 83.1 (17.6) 83.4 (16.9) 89.2 (14.8) <0.001
General Health (Fair or Poor) (n, %) 521 (22) 23 (30) 169 (37) 329 (18) <0.001
Tumor Grade (%) <0.001
Well to Moderately Differentiated 1630 (67) 30 (39) 338 (73) 1262 (67)
Poorly Differentiated or Unavailable� 795 (33) 46 (61) 127 (27) 622 (33)
Tumor Clinical T-Stage (%) <0.001
cT1 1,193 (49) 20 (26) 227 (49) 939 (50)
cT2 819 (34) 34 (45) 136 (29) 649 (34)
T3a or Unavailable�� 413 (17) 22 (29) 102 (22) 296 (16)
Primary Prostate Cancer Management (%) <0.001
Conservative 794 (33) 46 (60) 197 (42) 551 (29)
Radical Prostatectomy 323 (13) ~ 28 (6) 294 (16)
Radiation Therapy 1308 (54) ~ 240 (52) 1039 (55)
~ cell size <11 individuals for some sub-categories, exact n =, % not reportable per SEER-MHOS data use agreements; the race variable was utilized as five levels in all
analyses, including white, black, Hispanic, Asian-Pacific Islander, or other.
�The small percentage of ungraded tumors were not reported individually in this table due to cell size reporting limitations and represented <3% of the total sample.
��T3a tumors contributed less than 2% of the total sample; exact numbers were not reportable per SEER-MHOS data use agreements. Those without detailed T-stage
available (<3% of the sample) did not have regionalized/metastasized tumors, as confirmed by other SEER staging variables.
±PF-ADL is scored on a 0–100 point scale with 0 being worse and 100 being best and is not normalized to a mean of 50 points.
https://doi.org/10.1371/journal.pone.0240039.t001
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accurately predicting OCM risk for an individual patient remains challenging, our tool dem-
onstrated improved discrimination between individuals who lived and died, as compared to
estimates from currently recommended Social Security life tables [11]. Our tool also provided
more accurate individualized estimates of mortality risk than Social Security life tables, which
broadly overestimated risk for most patients in this study. These findings are particularly rele-
vant as over half of patients experiencing OCM within 10 years of diagnosis were treated
aggressively- predominantly with radiation, suggesting there may be room for improving our
patient selection. Conversely, only 40% of those experiencing prostate-specific mortality
underwent definitive treatment in this cohort of men over 65 –reinforcing the need to not sim-
ply rule out treatment for older individuals based on age alone.
The final predictors selected in this study were age, comorbidity, patient-reported general
health, smoking, and marital status. These have all been individually shown to predict mortal-
ity risk, but our model is the first to combine these factors in a single prognostic calculator
for 10-year OCM risk [3,7,13,14,18,26]. While age and comorbidity were the most important
predictors, patient-reported general health, smoking, and marital status made valuable
Table 2. Final adjusted model for the 10-year competing risk of other cause mortality.
Predictor β̂ Sub Hazard Ratio (SHR) 95% Confidence Interval Z-Score p-value for SHR Harrell’s c-index��
Age at diagnosis (1-year increments) 0.078 1.08 1.06–1.11 6.44 <0.001 0.586
Approximated Charlson Comorbidity Index Score 0.197 1.21 1.14–1.30 6.04 <0.001 0.660
Patient-reported general health 0.678
Poor vs. (excellent/very good/good) 1.010 2.75 1.83–4.13 5.47 <0.001
Fair vs. (excellent/very good/good) 0.623 1.86 1.49–2.33 4.84 <0.001
Smoker at diagnosis 0.530 1.70 1.32–2.18 4.15 <0.001 0.693
Marital status (all other vs. married) 0.307 1.36 1.12–1.66 3.04 0.002 0.701
An online risk calculator supplement is available at http://www.urologyrisk.com
Baseline Survival: 0.99948996
10-Year Overall Cumulative Incidence of Non-Prostate Mortality: 24.307%
Model Harrell’s c-index: 0.701
Over the observation period, the total number of OCM deaths = 495 Total PCSM deaths = 76
��Harrell’s c-index is reported as the c-index for the model including the predictor of interest and any predictors listed above it. For example, the value reported for
patient-reported general health is the c-index for a model with predictors: age, approximated Charlson Comorbidity Index Score, and the general health.
https://doi.org/10.1371/journal.pone.0240039.t002
Table 3. Range of 10-year other cause mortality risk predictions.






An online risk calculator supplement is available at http://www.urologyrisk.com
Risk scores were calculated as 1-(base survival)^(exp(Sb̂x))
�SEER-MHOS risk estimates are derived from the model developed in the primary analysis (Table 2)
Base survival was 0.99948996 for the SEER-MHOS data calculations. Sb̂x can be calculated as the sum of the (b̂
presented in Table 2 times the value for the covariate).
https://doi.org/10.1371/journal.pone.0240039.t003
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incremental contributions. Although we considered more detailed patient-reported assess-
ments of health impairment in the modeling process, additional variables did not improve
upon our final models’ ability to distinguish between those who lived and died.
There are a number of existing tools available for estimating geriatric life expectancy
[32,33], as well as tools developed for estimating OCM risk in men with prostate cancer
[3,7,13,14]. However, general geriatric tools require more extensive clinician inputs and are
designed for shorter-term risk evaluation [32,33]. Further, there has been limited clinical
adoption of existing tools for OCM risk estimation in men with prostate cancer [15,16]. Our
tool improves upon Social Security life table risk estimates by providing more accurate individ-
ualized OCM risk estimates and better discrimination between those living and dying. We
used reproducible patient-reported inputs and population-based data from men newly diag-
nosed with prostate cancer to promote the generalizability of our predictions. We facilitate use
by providing a supplemental online interface (http://www.urologyrisk.com). Risk scores can
be interpreted relative to the population risk distribution (provided in Table 3), rather than as
absolute values alone. For example, clinicians may consider focusing detailed discussions of
definitive therapies on patients who fall in the lower risk quartiles, who have a low risk of
dying within 10 years of diagnosis.
This work has several strengths and limitations. The generalizability of our findings may be
limited as MHOS surveys Medicare Advantage plan enrollees who, on average, have better
self-reported health and lower comorbidity burden than men enrolled in traditional fee-for
service Medicare [34]. This may mean that our model could possibly underestimate the abso-
lute OCM risk when applied to the general population of men over 65. However, prior work
has shown that, after appropriately adjusting for comorbidity burden and health status, out-
comes are comparable between Medicare Advantage and fee-for service patients [34]. We
would caution that external validation of our model is needed before broad utilization of our
risk estimates. Regarding comorbidities, while we captured the majority of conditions listed in
the Charlson Comorbidity index, we were unable to account for three conditions: end-stage
renal disease, liver failure, and peptic ulcer disease, which were not recorded in SEER-MHOS.
This may have contributed to our model’s overall modest utility for discrimination given a c-
index of 0.70 [17]. Furthermore, we would like to emphasize that if risk estimates from our
prediction model are applied to external data it is quite likely that the model may not discrimi-
nate as well as it has in this report. While our internal validation methods suggested minimal
optimism bias in our c-index estimates, no internal validation can substitute for a robust vali-
dation in external data. However, in comparison, the discrimination of the recommended
Social Security life tables would be considered of no clinical value (c-index 0.50–0.60) [17].
While our model discrimination is overall modest, it is important to also consider that a third
to a half of patients with prostate cancer die of events that may be difficult to predict (e.g., sub-
sequent development of other cancers, acute cardiac events and stroke) [18]. Thus, there may
be inherent limitations to how well any prognostic model can predict who will live and die
within 10-years until better disease markers are available that predict events that are currently
Table 4. Model calibration and comparison to social security life table estimates: Predicted vs. observed other cause mortality.
Quartile of Risk Low to
High
Mean SEER-MHOS Predicted % OCM
(95% CI)
Observed Cumulative Incidence of OCM
(95% CI)
Mean Social Security Life Table Predicted
Mortality (95% CI)
1 (n = 599) 12.4 (12.3–12.6) 10.7 (8.0–13.9) 31.0 (30.5–31.4)
2 (n = 599) 17.6 (17.5–17.7) 20.4 (16.8–24.4) 38.8 (38.2–39.4)
3 (n = 599) 23.8 (23.6–24.0) 22.3 (18.5–26.3) 45.3 (44.5–46.1)
4 (n = 599) 43.4 (42.3–44.5) 45.5 (40.4–50.5) 45.3 (44.5–46.1)
https://doi.org/10.1371/journal.pone.0240039.t004
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difficult to forecast. Additionally, we have opted not to incorporate definitive treatment deci-
sions into our model. This may lead our model to overestimate OCM risk among men who cli-
nicians would subjectively deem good candidates for definitive treatment and underestimate
OCM risk among men who clinicians would subjectively consider poor candidates for inter-
vention. Finally, because a high proportion of our population underwent initial definitive
treatment, our population may overall reflect a healthier cohort, which may lead our model to
underestimate absolute OCM risk in cohorts of men who are subjectively poor candidates for
intervention.
Conclusions
This study provides a prognostic tool which uses a simple set of patient-reported characteris-
tics that may better identify men at high and low risk of 10-year non-prostate cancer mortality
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